News >

Ibrutinib EU Indications Expanded in CLL and Waldenstrom Macroglobulinemia

Gina Columbus @ginacolumbusonc
Published: Tuesday, Aug 13, 2019

Alessandra Tedeschi MD

Alessandra Tedeschi MD
The European Commission has expanded the approval of ibrutinib (Imbruvica) to include use in combination with obinutuzumab (Gazyvaro, EU; Gazyva, US) for adult patients with previously untreated chronic lymphocytic leukemia (CLL), and also in combination with rituximab (Rituxan) for the treatment of adult patients with Waldenström macroglobulinemia (WM).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x